PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2018JCI Insight150 citationsOpen Access

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

SMStergios J. MoschosRSRyan J. SullivanWHWen-Jen Hwu

Key Points

Key points are not available for this paper at this time.

Abstract

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., and NIH (P01 CA168585 and R35 CA197633).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Moschos et al. (2018) studied this question.

synapsesocial.com/papers/69dd4adb7d97b7e86940c9eehttps://doi.org/10.1172/jci.insight.92352
Ask AI
Helpful
Bookmark
Share
View Full Paper